NCT03156504View on ClinicalTrials.gov

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

February 12, 2020

Study Completion Date

March 12, 2020

Conditions
Major DepressionBipolar I DisorderBipolar II DisorderUnipolar Depression
Interventions
DRUG

Ketamine Hydrochloride

Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.

Trial Locations (4)

21287

Johns Hopkins Hospital, Baltimore

45219

University of Cincinnati Medical Center, Cincinnati

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Network of Depression Centers

OTHER

lead

Mayo Clinic

OTHER

NCT03156504 - The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. | Biotech Hunter | Biotech Hunter